GENE ONLINE|News &
Opinion
Blog

2025-05-02|

Pharma M&A Deal Value Jumps 101% in Q1 2025, Fueled by Oncology Focus

by Mark Chiang
Share To

NEWSFLASH

Pharma mergers and acquisitions saw a significant increase in value during the first quarter of 2025, despite political uncertainty in the United States. A new report reveals deal value surged by 101% in this period, with oncology remaining the dominant therapeutic area. GlobalData’s report indicates that oncology assets were the primary target for most of the deals made during Q1 2025. This focus reflects the continued importance and investment in cancer-related research and development within the pharmaceutical industry.

Newsflash | Powered by GeneOnline AI
Date: May 2, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
A Look at Taiwan-German Collaborative Solutions in Precision Medicine, Drug Development, and Medical Tech
2025-05-21
LATEST
A Look at Taiwan-German Collaborative Solutions in Precision Medicine, Drug Development, and Medical Tech
2025-05-21
ACOG Updates Pain Management Guidelines for IUD Insertions as Novavax Vaccine Gains Approval
2025-05-20
NIH Restores Research Funding to Previously Defunded Scientists Amid Policy Shifts
2025-05-20
Prime Medicine Reduces Workforce by 25 Percent and Appoints David Schenkein as New CEO
2025-05-20
UnitedHealth Group Stock Drops Amid Rising Medicare Advantage Costs and Regulatory Debates
2025-05-20
Trump Science Adviser Michael Kratsios Calls for Renewed Focus on Reproducible Research Practices to Address Scientific Stagnation
2025-05-20
House Republicans Propose $700 Billion Medicaid Savings with Work Requirements
2025-05-20
EVENT
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top